| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 14 октября 2020 г. |
| Окончание: | 1 декабря 2023 г. |
| Описание: | Describe the safety, tolerability, efficacy and approaches to prescribing prolgolimab in the standard dosing regimen of 1 mg / kg every 2 weeks in patients with advanced melanoma in routine practice. Prolgolimab (Forteca, formerly BCD 100) is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 14 октября 2020 г. |
| Окончание: | 1 декабря 2023 г. |
| Описание: | Describe the safety, tolerability, efficacy and approaches to prescribing prolgolimab in the standard dosing regimen of 1 mg / kg every 2 weeks in patients with advanced melanoma in routine practice. Prolgolimab (Forteca, formerly BCD 100) is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | не указано |
| Начало: | 8 октября 2018 г. |
| Окончание: | 27 апреля 2019 г. |
| Описание: | Retrospective chart review Study of patients with BRAF V600 positive advanced (unresectable or metastatic) melanoma, who were treated with targeted therapy in routine clinical practice in Russian Federation |
| смотреть на ClinicalTrials.gov |